Involvement of the Syk–mTOR pathway in follicular lymphoma cell invasion and angiogenesis

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

Markus Guba, Philipp von Breitenbuch, Markus Steinbauer et al. · Nature Medicine · 2002 · 1.7K citations

Oncology, Angiogenesis, Metastatic Tumor Growth +9

The Identification of 2-(1<i>H</i>-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-<i>d</i>]pyrimidine (GDC-0941) as a Potent, Selective, Orally Bioavailable Inhibitor of Class I PI3 Kinase for the Treatment of Cancer

Adrian Folkes, Khatereh Ahmadi, W. Alderton et al. · Journal of Medicinal Chemistry · 2008 · 739 citations · Full text

Pi3 Kinase, Chemoprevention Strategy, Pharmacotherapy +18

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

Jonathan W. Friedberg, Jeff P. Sharman, John Sweetenham et al. · Blood · 2009 · 734 citations · Full text

R406, an Orally Available Spleen Tyrosine Kinase Inhibitor Blocks Fc Receptor Signaling and Reduces Immune Complex-Mediated Inflammation

Sylvia Braselmann, Vanessa Taylor, H. Zhao et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 508 citations

Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP‐9

Jingsong Chen, Qian Wang, Xinhui Fu et al. · Hepatology Research · 2009 · 346 citations · Full text